

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Edmond DIFFERDING et al. :  
Serial No. NEW : **Attn: APPLICATION BRANCH**  
Filed October 28, 2003 : Attorney Docket No. 2003\_1547

2-OXO-1-PYRROLIDINE DERIVATIVES,  
PROCESSES FOR PREPARING THEM AND  
THEIR USES

**(Rule 1.53(b) Divisional of Serial No. 10/204,266,  
Filed August 20, 2002)**

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of [X] the references listed on attached form PTO-1449 and/or [] the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No. 10/204,266.

1a.  This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

1b.  This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1)  the certification of paragraph 2 below is provided, **or**

(2)  the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c.  This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and**

**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

a.  that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b.  that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3.  Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
  - a.  a full or partial English language translation submitted herewith,
  - b.  a foreign patent office search report (in the English language) submitted herewith,
  - c.  the concise explanation contained in the specification of the present application at page ,
  - d.  the concise explanation set forth in the attached English language abstract,
  - e.  the concise explanation set forth below or on a separate sheet attached to the reference:
5.  A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Edmond DIFFERDING et al.

By Matthew Jacob  
Matthew Jacob  
Registration No. 25,154  
Attorney for Applicants

MJ/asd  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
October 28, 2003

FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary )  Date Submitted to PTO: October 28, 2003			ATTY DOCKET NO. 2003_1547	SERIAL NO. [NEW]			
			APPLICANT Edmond DIFFERDING et al.				
			FILING DATE October 28, 2003	GROUP			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2,836,599	5/1958	Frankel et al.			
	AB	4,943,639	7/1990	Gobert et al.			
	AC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AD	99/13911	3/1999	PCT			
	AF	1,309,692	3/1973	Great Britain			
	AF						
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AG	Prous: Drugs of the Future, ES, Barcelona, Vol. 19, No. 2, pp. 111-113 (1994)					
	AH	Fischer et al.: Pharmazie, Vol. 46, pp. 359-360 (1991)					
	AI	Chemical Abstracts, Vol. 95, No. 3, page 661, Abstract No. 24693r (1981)					
	AK	Glozman et al.: Khim.-Farm. ZH., Vol. 14, No. 11, pp. 43-8 (1980)					
	AL	Banfi et al.: Farmaco, Ec. Sci., Vol. 39, No. 1, pp. 16-22 (1984)					
	AM	Pellegata et al.: Farmaco, Ec. Sci., Vol. 36, No. 10, pp. 845-5 (1981)					
	AN	Pinza et al.: Farmaco, Ed. Sci., Vol. 33, No. 2, pp. 130-41 (1978)					
	AO	Pifferi et al.: Farmaco, Ed. Sci., Vol. 32, No. 8, pp. 602-13 (1977)					
EXAMINER				DATE CONSIDERED			

FORM PTO 1449 ( <i>modified</i> )  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary )  Date Submitted to PTO: October 28, 2003			ATTY DOCKET NO. 2003_1547	SERIAL NO. [NEW]			
			APPLICANT Edmond DIFFERDING et al.				
			FILING DATE October 28, 2003	GROUP			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AD						
	AE						
	AF						
OTHER DOCUMENT(S) ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )							
	AI	Sugawara et al.: Arzneimittel Forschung. Drug. Research, Editio Cantor. Aulendorf, DE, Vol. 44, No. 1, pp. 211-213 (1994)					
	AH	Vettinger et al.: Liebigs Ann. Chem., Vol. 2, pp. 195-201 (1990)					
	AI	Elliott et al.: Journal of Medicinal Chemistry, Vol. 37, No. 11, pp. 1562-1568 (1994)					
	AI	Lehmann et al.: Heterocycles, Vol. 51, No. 6, pp. 1389-1400 (1999)					
	AL	Almeida et al.: Tetrahedron: Asymmetry, Vol. 3, No. 11, pp. 1431-1440 (1992)					
	AM	Chemical Abstracts, Vol. 52, No. 10, Abstract No. 2007i (1958)					
	AN	Koelsch et al., J. Org. Chem., Vol. 21, pp. 1211-13 (1956)					
	AO	Database Beilstein 'Online!', Beilstein Institute for Organic Chemistry, Database accession no. 13551					
EXAMINER				DATE CONSIDERED			

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) <i>(Use several sheets if necessary)</i> Date Submitted to PTO: October 28, 2003			ATTY DOCKET NO. 2003_1547		SERIAL NO. [NEW]			
			APPLICANT Edmond DIFFERDING et al.					
			FILING DATE October 28, 2003			GROUP		
			U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA							
	AB							
	AC							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AD							
	AE							
	AF							
OTHER DOCUMENT(S) <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
	AG	Sugasawa: Chem. Zentralbl., Vol. 98, No. II, page 932 (1927)						
	AH	Thorsett et al., Journal of Medicinal Chemistry, Vol. 29, No. 2, pp. 251-260 (1986)						
	AI	Database Beilstein 'Online!', Beilstein Institute for Organic Chemistry, Database accession no. 6922620						
	AK	Keusenkothen et al.: J. Chem. Soc. Perkin Trans1, Vol. 17, pp. 2485-92 (1994)						
	AL	Thaisrivongs et al., Journal of Medicinal Chemistry, Vol. 31, No. 7, pp. 1369-1376 (1988)						
	AM	Glozman et al., 1981, CAS:95:24693						
	AN	Kometani et al., 1991, CAS:115:126869						
	AO							
EXAMINER				DATE CONSIDERED				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.